Tracer library / [18F]fluspidine
[18F]fluspidine
Also written as [18F]fluspidine
- Radionuclide
- F-18 t½ 109.77 min
- Modality
- PET
- Production route
- —
- Stage
- Clinical research
- Syntheses indexed
- 1
What it is
- Compound class
- Spirocyclic piperidine (fluspidine, σ1 receptor ligand)
- Target / mechanism
- σ1 receptor ligand PMID 38399380
- Clinical application
- PET imaging of σ1 receptors in the brain of patients with major depressive disorder and Huntington's disease (pridopidine occupancy study) PMID 38399380
- Theranostic pair
- —
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| TRACERlab FX FN GE HealthCare | — | HPLC+SPE | 37±8% | 99.3±0.5% | tosylate precursor | 24291352 2014 Appl Radiat Isot was implemented on a TRACERlab(TM) FX F-N synthesizer - produced within 59±4 min with an overall radiochemical yield of 37±8% |
Need this precursor?We can point you to suppliers for [18F]fluspidine, or handle the enquiry for you.
Get in touchQuality control Preliminary - inferred from compound class
- Ph. Eur. monograph
- not verified No Ph. Eur. check is recorded for this entry.
- USP monograph
- not verified No USP check is recorded for this entry.
How this set was arrived at. base set per Ph. Eur. general monograph 0125 (rule); organic-phase radiosynthesis assumed from isotope/compound class, no synthesis data confirming it -> GC residual solvents (preliminary); conventional nucleophilic 18F-fluorination assumed from isotope/compound class, no synthesis data confirming K222 use -> Kryptofix test (preliminary)
Tests listed by reference only. Monograph texts are copyrighted and are not reproduced here. How these are derived
Setting up quality control?We can help you scope the equipment needed to release [18F]fluspidine.
Get in touchNotes
Added from reverse module search (stage 6); 3 article(s) with F-18. Stage set/updated at stage 23 from PMID 38399380: 'In the first clinical trial, (S)-[18F]2 was used to visualize σ1 receptors in the brains of patients with major depressive disorder (MDD).'. | Stage 28: added indication(s) neu-huntington from consolidated missing-rubric review. | Stage 30 (2026-09-18): Stage was 'first-in-human / first clinical trial'; normalised to 'Clinical research', original wording kept here.